ArticleLipids in health and disease2026
Rethinking the lipid paradox: the role of baseline characteristics in LDL-C and long-term mortality after acute myocardial infarction.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- The Lipid Paradox in Statin-Naïve Patients with a First ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: A Confounded, Not Protective, Association.Journal of clinical medicine · 2026Article
- Unsupervised cardiometabolic phenotyping unmasks residual MACCE risk beyond LDL-C in acute myocardial infarction after revascularization.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious observations have reported inconsistent results on the association between low-density lipoprotein cholesterol (LDL-C) at presentation and long-term outcomes after acute myocardial infarction (AMI). We aimed to clarify the potential impact of baseline characteristics on the inverse association between LDL-C and all-cause mortality, known as the lipid paradox.
methodsA total of 1,305 critically ill patients with AMI from the Medical Information Mart for Intensive Care IV database were included in the analysis. Patients were stratified according to LDL-C quartiles. The primary outcome was 180-day and 360-day all-cause mortality. Baseline characteristics were included in stepwise Cox regression models. Restricted cubic spline analyses across multiple models and subgroups were performed to assess the influence of baseline characteristics on the association between LDL-C and long-term outcomes.
resultsA total of 244 (18.7%) and 291 (22.3%) mortality events occurred at 180 and 360 days of follow-up, respectively. Patients in the lowest LDL-C quartile had the highest all-cause mortality at both 180 and 360 days (28.7% and 35.2%, respectively). After stepwise adjustment for baseline covariates, the J-shaped relationship observed in the unadjusted model was gradually attenuated and disappeared. The inverse association between LDL-C and mortality was more pronounced in subgroups characterized by elevated mortality risk, including patients with low albumin levels, elevated neutrophil-to-lymphocyte ratio, and higher SOFA scores. Nevertheless, in-hospital statin use was consistently associated with reduced all-cause mortality across nearly all subgroups.
conclusionsThe lipid paradox observed in critically ill patients with AMI is attributed to differences in baseline characteristics across LDL-C strata. After adjusting for potential confounders, baseline LDL-C was not an independent predictor of long-term mortality in AMI. Lipid-lowering therapy was associated with favorable long-term outcomes irrespective of baseline LDL-C levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.